HRMY - Harmony Biosciences Holdings, Inc. Stock Price, Fair Value and News

$34.28+0.39 (+1.15%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HRMY Price Action

Last 7 days

5.8%

Last 30 days

4.5%

Last 90 days

-12.7%

Trailing 12 Months

6.2%

HRMY RSI Chart

HRMY Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

15.94

Price/Sales (Trailing)

2.87

EV/EBITDA

8.81

Price/Free Cashflow

8.88

HRMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HRMY Fundamentals

HRMY Revenue

Revenue (TTM)

681.9M

Rev. Growth (Yr)

16.08%

Rev. Growth (Qtr)

7.65%

HRMY Earnings

Earnings (TTM)

122.6M

Earnings Growth (Yr)

19.84%

Earnings Growth (Qtr)

297.66%

HRMY Profitability

EBT Margin

25.71%

Return on Equity

20.55%

Return on Assets

13.21%

Free Cashflow Yield

11.26%

HRMY Investor Care

Buy Backs (1Y)

2.63%

Diluted EPS (TTM)

2.12

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	617.5M	656.1M	681.9M	0
2023	471.7M	498.9M	541.9M	582.0M
2022	331.1M	364.3M	400.8M	437.9M
2021	199.6M	235.4M	270.5M	305.4M
2020	44.4M	82.9M	121.3M	159.7M
2019	0	0	0	6.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO	Dr. Jeffrey M. Dayno M.D.
WEBSITE	harmonybiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	200

Harmony Biosciences Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Harmony Biosciences Holdings, Inc.? What does HRMY stand for in stocks?

HRMY is the stock ticker symbol of Harmony Biosciences Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harmony Biosciences Holdings, Inc. (HRMY)?

As of Fri Dec 20 2024, market cap of Harmony Biosciences Holdings, Inc. is 1.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRMY stock?

You can check HRMY's fair value in chart for subscribers.

Is Harmony Biosciences Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether HRMY is over valued or under valued. Whether Harmony Biosciences Holdings, Inc. is cheap or expensive depends on the assumptions which impact Harmony Biosciences Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRMY.

What is Harmony Biosciences Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, HRMY's PE ratio (Price to Earnings) is 15.94 and Price to Sales (PS) ratio is 2.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRMY PE ratio will change depending on the future growth rate expectations of investors.